Antituberculosis drug-induced hepatotoxicity in children (Q35096954)

6 August 2017

1 reference

title

Antituberculosis drug-induced hepatotoxicity in children (English)

1 reference

6 August 2017

1 reference

Peter R Donald

1

1 reference

6 August 2017

publication date

1 June 2011

1 reference

6 August 2017

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

e16

1 reference

Creative Commons Attribution 4.0 International

6 August 2017

copyright license

start time

20 June 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Treatment of paediatric TB: revised WHO guidelines

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

An official ATS statement: hepatotoxicity of antituberculosis therapy

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Adherence to isoniazid preventive chemotherapy: a prospective community based study

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Tuberculosis prevention in Mexican immigrants: limitations of short-course therapy

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

ISONIAZID, PARA-AMINOSALICYLIC ACID, AND STREPTOMYCIN INTOLERANCE IN 1,744 PATIENTS. AN ANALYSIS OF REACTIONS TO SINGLE DRUGS AND DRUG GROUPS PLUS DATA ON MULTIPLE REACTIONS, TYPE AND TIME OF REACTIONS, AND DESENSITIZATION

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Icterus and febrile reactions in response to isonicotinic acid hydrazine; report of two cases and review of the literature

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

An Algerian experiment: short chemotherapy for tuberculosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Twice weekly tuberculosis preventive therapy in HIV infection in Zambia

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Acute liver failure caused by isoniazid in a child receiving carbamazepine

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Rifampin preventive therapy for tuberculosis in Boston's homeless.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Frequency and type of reactions to antituberculosis drugs: observations in routine treatment

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Successful liver transplantation for isoniazid-induced hepatic failure--a case report

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Hepatotoxicity caused by the combined action of isoniazid and rifampicin

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Risk Factors for Isoniazid (INH)-Induced Liver Dysfunction

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

The use of isoniazid among household contacts of open cases of pulmonary tuberculosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Prophylactic Effect of Isoniazid in Young Tuberculin Reactors

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Our experience with Rifampicin

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Isoniazid-associated hepatitis. Report of an outbreak

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Drug-induced hepatitis during a treatment associating isoniazid and rifampicin

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Rifampicin, a general review

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Controlled chemoprophylaxis trials in tuberculosis. A general review

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

A case of isoniazid hepatitis in a child

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Isoniazid administration and liver injury

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Tuberculosis in a primary school: the Uppingham outbreak

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

The treatment of tuberculosis in children

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Isoniazid prophylaxis in hepatitis B carriers

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Fatal isoniazid hepatitis in a child

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Reduced incidence of tuberculosis by prophylactic chemotherapy in subjects showing strong reactions to tuberculin testing

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Good tolerance of pyrazinamide in children with pulmonary tuberculosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Twenty isoniazid-associated deaths in one state

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

[Hepatotoxicity of the combination of isoniazid-rifampicin in African children. Role of malnutrition and HB virus].

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Isoniazid-rifampin-induced hepatitis in hepatitis B carriers

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Criteria of drug-induced liver disorders. Report of an international consensus meeting

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Short course chemotherapy for tuberculous lymphadenitis in children

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Tuberculosis in children: a 13-year follow up of 1714 patients in a Belgian home care centre.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Tuberculosis in children 10 years of age and younger: three decades of experience during the chemotherapeutic era

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Isoniazid-associated hepatitis deaths: a review of available information

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Perspective: preventive isoniazid therapy and the liver

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Intensive short course chemotherapy for tuberculous meningitis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Fatal hepatic necrosis due to isoniazid chemoprophylaxis in a 15-year-old girl

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Hepatotoxicity of rifampicin and isoniazid in children

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Hepatitis cases in isoniazid treated groups and in a control group

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Hepatic toxicity of antituberculous drugs in children

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Isoniazid hepatitis in adolescents

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Rifampin in treatment of tuberculous meningitis in children

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Hepatic involvement in childhood tuberculosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Clinical hepatotoxicity of isoniazid in children

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Isoniazid liver injury during chemoprophylaxis in children

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Isoniazid Hepatotoxicity in Children

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Unintended consequences: mandatory tuberculin skin testing and severe isoniazid hepatotoxicity

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Hepatotoxicity of pyrazinamide: cohort and case-control analyses

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Monitoring and management of antituberculosis drug induced hepatotoxicity

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Category based treatment of tuberculosis in children.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Central nervous system tuberculosis in children: 2. Treatment and outcome

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Twice weekly vs. daily chemotherapy for childhood tuberculosis.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Intensive short course chemotherapy in the management of tuberculous meningitis.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Clinical features, diagnosis, and treatment of tuberculosis in infants

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Hydrazine production in children receiving isoniazid for the treatment of tuberculous meningitis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133498

Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis

27 September 2018

1 reference

12 December 2020

[Toxic effects of isonicotinic acid hydrazide; suicide with neoteben]

1 reference

12 December 2020

Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis?

1 reference

12 December 2020

Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic

1 reference

12 December 2020

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection

1 reference

12 December 2020

Hepatic toxicity during chemotherapy for severe tuberculosis meningitis

1 reference

12 December 2020

Effect of Rifampicin and Isoniazid on Liver Function

1 reference

12 December 2020

Editorial: Isoniazid and the liver

1 reference

12 December 2020

Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin

1 reference

12 December 2020

[Hepatic toxicity of antitubercular agents. Role of different drugs. 199 cases]

1 reference

12 December 2020

A clinical, functional, and needle biopsy study of the liver in pulmonary tuberculosis

1 reference

12 December 2020

Hepatic function in relation to acetylator phenotype in children treated with antitubercular drugs

1 reference

12 December 2020

Hydrazide-rifampicin: hepatotoxicity in children

1 reference

12 December 2020

[On a case of fatal isoniazid poisoning]

1 reference

12 December 2020

Hepatic involvement in extrapulmonary tuberculosis; histologic and functional characteristics

1 reference

12 December 2020

Isoniazid-rifampin--induced fulminant liver disease in an infant

1 reference

12 December 2020

Three chemotherapy studies of tuberculous meningitis in children

1 reference

12 December 2020

Acute hepatic failure in seven patients after prophylaxis and therapy with antituberculous agents. Successful treatment with orthotopic liver transplantation

1 reference

12 December 2020

[Liver damage in treatment of latent tuberculous infection by isoniazid]

1 reference

12 December 2020

Short course chemotherapy for tuberculosis in children

1 reference

12 December 2020

Isoniazid prophylaxis in an undeveloped area

1 reference

12 December 2020

Short-course chemotherapy for tuberculosis in children

1 reference

12 December 2020

Hepato-biliary effects of the combination rifampicin-isoniazid. I. Histological study in rats

1 reference

12 December 2020

Intensive short-course chemotherapy in pulmonary tuberculosis

1 reference

12 December 2020

Pyrazinamide-isoniazid in tuberculosis

1 reference

12 December 2020

Rifampin plus isoniazid in initial therapy of pulmonary tuberculosis and rifampin and ethambutol in retreatment cases

1 reference

12 December 2020

Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children

1 reference

12 December 2020

Fatal hepatic necrosis secondary to isoniazid therapy

1 reference

12 December 2020

[Therapy of tuberculosis with neoteben (isonicotinic acid hydrazide).]

1 reference

12 December 2020

Tuberculous meningitis developing in the course of isoniazid therapy

1 reference

12 December 2020

[The liver in tuberculosis in children; histological studies of punch biopsy material.]

1 reference

12 December 2020

Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks

1 reference

12 December 2020

Hepatic enzyme abnormalities in children on triple therapy for tuberculosis

1 reference

12 December 2020

Should primary tuberculosis in children continue to be neglected?

1 reference

12 December 2020

Hydrazine derivatives of isonicotinic acid (rimifon marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report

1 reference

12 December 2020

1 reference

12 December 2020

The treatment of tuberculous meningitis in children with a combination of isoniazid, rifampicin and streptomycin—preliminary report

1 reference

12 December 2020

Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy

1 reference

12 December 2020

Rifampicin in combination with isoniazid in the treatment childhood tuberculosis

1 reference

12 December 2020

[Liver damage caused by isoniazid in small children]

1 reference

12 December 2020

Therapy of tuberculosis with Rifampicin in childhood (author's transl)

1 reference

12 December 2020

Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents

1 reference

12 December 2020

Needle biopsy of the liver in various forms of childhood tuberculosis

1 reference

12 December 2020

Serum enzyme changes in patients receiving antituberculosis therapy with rifampicin or p-aminosalicylic acid, plus isoniazid and streptomycin

1 reference

12 December 2020

Acute viral hepatitis as a confounding factor in patients with antituberculosis treatment induced hepatotoxicity

1 reference

12 December 2020

Preventive effects of isoniazid in the treatment of primary tuberculosis in children

1 reference

12 December 2020

Hepatotoxicity of the rifampicin-isoniazid combination in children

1 reference

12 December 2020

Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month

1 reference

12 December 2020

[Functional studies on the question of liver damage by isoniazid in children]

1 reference

12 December 2020

Short course chemotherapy for tuberculosis in children

1 reference

12 December 2020

Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis

1 reference

12 December 2020

Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis

1 reference

12 December 2020

Pyrazinamide-isoniazid in tuberculosis. III. Observations with reduced dosage of pyrazinamide

1 reference

12 December 2020

Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin

1 reference

12 December 2020

New drugs in the treatment of primary tuberculosis

1 reference

12 December 2020

Isoniazid preventive therapy: Retrospect and prospect

1 reference

12 December 2020

Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of the effectiveness in children

1 reference

12 December 2020

The treatment of primary tuberculosis in children; results of a controlled study using isoniazid

1 reference

12 December 2020

Jaundice after rifampicin

1 reference

12 December 2020

Six-month isoniazid-rifampin treatment for pulmonary tuberculosis in children

1 reference

12 December 2020

Hepatotoxicity of isoniazid and rifampin in children

1 reference

12 December 2020

[A short 6-month period of drug therapy in childhood pulmonary tuberculosis (preliminary report)]

1 reference

12 December 2020

Liver biopsy in a tuberculosis hospital

1 reference

12 December 2020

Liver enzyme disturbances during isoniazid chemoprophylaxis in children

1 reference

12 December 2020

Role of isoniazid in hepatotoxicity with the INH-rifampicin combination in tuberculosis in children

1 reference

12 December 2020

Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin

1 reference

12 December 2020

Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis

1 reference

12 December 2020

Cortisone and corticotropin in the treatment of tuberculosis in infancy and childhood

1 reference

12 December 2020

Management and outcome of chemotherapy for childhood tuberculosis. Medical Research Council Tuberculosis and Chest Diseases Unit

1 reference

12 December 2020

Isonicotinic acid hydrazide in the treatment of tuberculous meningitis in children

1 reference

12 December 2020

Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide

1 reference

12 December 2020

Isoniazid prophylaxis in tuberculin reactors

1 reference

12 December 2020

Intensive short course chemotherapy for treatment of Greek children with tuberculosis

1 reference

12 December 2020

Severe hepatitis induced by chemotherapy with antitubercular agents in childhood. 2 cases

1 reference

12 December 2020

More adverse reactions to rifampicin

1 reference

12 December 2020

A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council

1 reference

12 December 2020

Fulminant hepatitis during treatment with rifampicin, pyrazinamid and ethambutol

1 reference

12 December 2020

Toxic hepatitis with jaundice occuring in a patient treated with isoniazid

1 reference

12 December 2020

Rifampicin in treatment of gangliopulmonary forms of initial tuberculosis in young infants and children

1 reference

12 December 2020

Pharmacology of isonicotinic acid hydrazide (nydrazid)

1 reference

12 December 2020

Systematic treatment of primary tuberculosis

1 reference

12 December 2020

Isoniazid hepatotoxicity in childhood

1 reference

12 December 2020

Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents

1 reference

12 December 2020

[Side-effects in isoniazid therapy of tuberculosis in children]

1 reference

12 December 2020

The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study

1 reference

12 December 2020

[Pharmacology, toxicology and clinical use of pyrazinamide (author's transl)]

1 reference

12 December 2020

Jaundice due to isoniazid

1 reference

12 December 2020

Functional hepatic impairment in pulmonary tuberculosis

1 reference

12 December 2020

Possible isoniazid-induced hepatotoxicity in a two-year-old child

1 reference

12 December 2020

[Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood--a pilot project]

1 reference

12 December 2020

Hepatotoxicity of rifampicin and isoniazid in children treated for tuberculosis

1 reference

12 December 2020

Identifiers

DOI

10.4081/PR.2011.E16

1 reference

6 August 2017

1 reference

6 August 2017

1 reference